Center for Vision Science, Ruhr University Eye Clinic, Bochum, Germany.
Ophthalmology. 2011 Dec;118(12):2382-8. doi: 10.1016/j.ophtha.2011.05.030. Epub 2011 Aug 27.
To determine the effectiveness of a light-adjustable intraocular lens (LAL) that can be adjusted postoperatively using ultraviolet (UV) irradiation.
A prospective, nonrandomized clinical trial was conducted at Center for Vision Science, Ruhr University Eye Clinic, in Bochum, Germany.
We included 122 eyes of 91 patients with significant cataract.
All patients had a visually significant cataract and were willing to volunteer for the trial. Participants underwent small-incision phacoemulsification followed by implantation of a LAL and were treated with a spatially profiled UV light delivered by a digital light delivery device to induce a targeted spherical and cylindrical refractive change postoperatively. Once the desired correction was achieved, the LAL was treated again to lock in the lens power. Distance visual acuity and manifest refraction was determined with follow-up time to determine the achieved refractive corrections and their stability.
We measured uncorrected visual acuity and best corrected visual acuity achieved versus targeted refractive outcome and refractive stability with a follow-up time of 18 months.
Residual postoperative refractive errors of 0.96 ± 0.85 diopters (D) in sphere and -0.98 ± 0.50 D in cylinder were corrected and stable over a follow-up time of 18 months. Final refraction achieved was 0.03 ± 0.17 D in spherical equivalent refraction.
Residual spherocylindrical errors up to 2.25 D in sphere and -2.75D in cylinder were successfully corrected with precision. The LAL technology has the potential individually to correct postoperative refractive errors precisely. The achieved refractive corrections are stable for up to 18 months.
FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any of the materials discussed in this article.
确定一种可通过紫外线（UV）照射术后调节的光调节型人工晶状体（LAL）的有效性。
在德国波鸿鲁尔大学眼科中心的视觉科学中心进行了一项前瞻性、非随机临床试验。
我们纳入了 91 名患者的 122 只眼，这些患者患有明显的白内障。
所有患者均患有明显的白内障，并愿意参与该试验。参与者接受小切口超声乳化白内障吸除术，然后植入 LAL，并使用数字光输送设备提供的空间分布 UV 光进行治疗，以在术后诱导靶向的球形和圆柱状屈光变化。一旦达到所需的矫正效果，就再次治疗 LAL 以锁定镜片功率。通过随访时间确定距离视力和明显的屈光状态，以确定实现的屈光矫正及其稳定性。
我们测量了未矫正视力和最佳矫正视力与目标屈光结果的对比，并在 18 个月的随访时间内评估了屈光稳定性。
术后残留的屈光误差为 0.96±0.85 屈光度（D）球镜和-0.98±0.50 D 柱镜，在 18 个月的随访时间内稳定不变。最终的屈光度为 0.03±0.17 等效球镜。
高达 2.25 D 球镜和-2.75 D 柱镜的残留球柱镜误差被精确矫正。LAL 技术具有精确矫正术后屈光误差的潜力。实现的屈光矫正在 18 个月内保持稳定。
作者在本文讨论的任何材料中均无专有或商业利益。
